Nanoparticle Organ Biodistribution & Risk Simulator

Inject a dose of nanoparticles and watch a real compartmental pharmacokinetic model route them between the bloodstream, liver, spleen, kidneys and a target tissue in 3D. Particle diameter, surface charge and PEG stealth-coating all feed directly into the governing rate constants — a small, neutral, heavily PEGylated particle clears through the kidneys in seconds, while a large, charged, uncoated one is swept up by the liver and spleen's macrophages and can linger for the entire simulation. This size/charge/coating trade-off is exactly the biodistribution uncertainty that drives real nanomedicine safety assessments and nanoethics debates about consent, long-term toxicity and equitable access to nanoscale therapies.